This opportunity seeks a contractor to examine the health benefits of GLP-1 receptor agonists versus DPP-4 inhibitors for people living with HIV, focusing on alcohol and substance use disorder outcomes using VA electronic health record data. The anticipated period of performance begins August 7, 2026, through August 6, 2027, with three optional one-year extensions. No specific budget amount is provided. Services will be performed using data from the Department of Veterans Affairs, the largest integrated healthcare system in the US. The government will award a firm fixed-price purchase order based on technical capability, past performance, and price.